869893-91-4

Basic information

• Product Name: Zinc, bromo[(3-chloro-2-fluorophenyl)methyl]-
• CAS NO: 869893-91-4
• Molecular Formula: C7H5BrClFZn
• Molecular Weight: 288.862
• Mol File: 869893-91-4.mol
• Article Data: 11

Chemical Properties

• CAS DataBase Reference: Zinc, bromo[(3-chloro-2-fluorophenyl)methyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Zinc, bromo[(3-chloro-2-fluorophenyl)methyl]-(869893-91-4)
• EPA Substance Registry System: Zinc, bromo[(3-chloro-2-fluorophenyl)methyl]-(869893-91-4)

Safety Data

• Hazardous Substances Data: 869893-91-4(Hazardous Substances Data)

Upstream product

• 85070-47-9 1-(bromomethyl)-3-chloro-2-fluorobenzene 
• 7440-66-6 zinc 

Downstream Products

• 1036647-77-4 3-(tert-butyl-dimethyl-silanyloxy)-7-(3-chloro-2-fluoro-benzyl)-4-oxo-4H-pyrido[1,2-a]pyrimidine-2-carboxylic acid methyl ester 
• 949465-78-5 methyl 5-(3-chloro-2-fluorobenzyl)-2,4-dimethoxybenzoate 
• 949465-76-3 5-(3-chloro-2-fluorobenzyl)-2-fluoro-4-methoxybenzoic acid methyl ester 
• 1177256-60-8 1-((2S)-1-tert-butyldimethylsilyloxypropan-2-yl)-6-(3-chloro-2-fluorobenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid ethyl ester 
• 1177256-62-0 1-((2R)-1-tert-butyldimethylsilyloxypropan-2-yl)-6-(3-chloro-2-fluorobenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid ethyl ester 
• 1177256-65-3 1-((2S)-1-tert-butyldimethylsilyloxypentan-2-yl)-6-(3-chloro-2-fluorobenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid ethyl ester 
• 1177256-67-5 1-((1S)-2-tert-butyldimethylsilyloxy-1-cyclohexylethyl)-6-(3-chloro-2-fluorobenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid ethyl ester 
• 1177256-70-0 1-((1S)-2-tert-butyldimethylsilyloxy-1-phenylethyl)-6-(3-chloro-2-fluorobenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid ethyl ester 
• 1177256-72-2 C₃₀H₃₈ClF₂NO₄Si 
• 1177256-74-4 1-((2R)-1-tert-butyldimethylsilyloxy-3-methylbutan-2-yl)-6-(3-chloro-2-fluorobenzyl)-7-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid ethyl ester 
• 1177256-76-6 1-((1S)-2-tert-butyldimethylsilyloxy-1-cyclohexylethyl)-6-(3-chloro-2-fluorobenzyl)-7-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid ethyl ester 
• 880870-67-7 C₁₃H₁₀ClF₂NO 
• 1177256-05-1 6-(3-chloro-2-fluorobenzyl)-1-((2R)-1-hydroxy-3-methylbutan-2-yl)-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 
• 697761-98-1 elvitegravir 

Relevant articles and documents

An Improved Synthesis of Elvitegravir

An improved process for the active pharmaceutical ingredient of a new HIV integrase inhibitor elvitegravir (1) has been developed. It starts from commercially available 2,4-dimethoxyacetophenone, which is selectively halogenated into the position 5. The 5-halo acetophenones are condensed with dialkyl carbonates to give the corresponding benzoylacetates. Their treatment with N,N-dimethylformamide dimethyl acetal followed by (S)-valinol then provided the corresponding intermediate benzoyl acrylates. Cyclization to the required 1,4-dihydroquinolin-4-oxo derivatives by aromatic nucleophilic substitution of the 2-methoxy group was achieved by treatment with N,O-bis(trimethylsilyl)-acetamide, which also protected the OH group as the trimethylsilyl derivative. Finally, the Negishi coupling with 2-fluoro-3-chlorobenzylzinc bromide and the following hydrolysis provided elvitegravir (1). The preferred variant, the seven-step procedure starting from 2,4-dimethoxyacetophenone, provides elvitegravir in 29.3% yield.

NOVEL COMPOSITIONS AND METHODS OF USE

Described herein are novel enzyme inhibitors. In some embodiments the enzyme inhibitors are integrase inhibitors, particularly HIV integrase inhibitors. Also described herein are compositions containing them and methods of using them. Thus, the compounds and compositions described herein are useful for the in vitro and in vivo inhibition of HIV integrase as a method of treating or preventing HIV, AIDS or related disorders.

DEUTERATED 4 -OXOQUINOLINE DERIVATIVES FOR THE TREATMENT OF HIV INFECTION

This invention relates to novel compounds that are 4-oxoquinoline derivatives and pharmaceutically acceptable salts thereof. More specifically, this invention relates to novel 4-oxoquinoline derivatives that are derivatives of elvitegravir. This invention